Participated · Series B · Mar 2022

Arima Genomics leverages whole‑genome sequence and structural information to provide comprehensive, clinically actionable cancer therapy selection insights. Its proprietary platform captures how DNA is organized inside the nucleus, uniting chromatin architecture with sequence data in a single readout that uncovers gene fusions and rearrangements missed by other tests. The technology is already reaching patients through the company’s CLIA‑certified Aventa clinical testing laboratory in Orlando, Florida. Under new leadership, Arima plans to build on a decade of discovery‑driven research and launch a focused pipeline of clinical assays to expand the platform’s impact. The company is strengthening its focus on transforming oncology testing and accelerating clinical expansion. Arima is headquartered in Carlsbad, California. Arima Genomics, based in San Diego, develops 3D genomics technologies that connect DNA sequence and structural data to reveal biological insights that linear sequencing misses. Its products preserve and present the structural organization of the genome to drive discovery in genome biology and human health. The company’s solutions are used across applications including cancer, neurobiology, immunology, and translational medicine, and support development and optimization of approaches such as cell- and gene-based therapies and precision oncology research. Arima reports more than 600 global customers and has been cited in over 200 peer-reviewed studies. The company says it will expand its product portfolio and bioinformatics capabilities and scale operational and commercial capacity worldwide. Investors backing the company include both new and existing strategic and VC partners such as Genetron Health, Agilent Technologies, and Vectr Ventures. Arima Genomics builds research tools centered on its Arima HiC platform to enable analysis of genome sequence together with 3D genome structure. The company plans to expand commercial efforts and to develop new applications for the HiC platform, including adding structural analysis capabilities to conventional chromatin immunoprecipitation via HiChIP. Arima is also developing new products such as smooth-coverage HiC for gap-less de novo assemblies and population sequencing. The financing will support scaling of operations and enhancements to customer service and support. Since its initial product launch in 2018, Arima reports rapid customer and revenue growth. The company frames its technology as accelerating understanding of genome sequence and structure toward roles in human health and disease.

Led · Series A · May 2021

TellBio, founded in 2019 and based in Beverly, Massachusetts, develops a proprietary circulating tumor cell (CTC) technology (TellDx) and a complementary therapeutics platform (TellRx). TellDx is a microfluidic diagnostic solution designed to detect live CTCs from patient liquid biopsies and is described as revenue-generating. TellRx is an early-stage therapeutics platform focused on generating anti-cancer medicines that specifically target CTCs. The company’s CTC approach and technology are exclusively licensed from Massachusetts General Hospital and originate from decades of academic and clinical research by its scientific founders. TellBio plans to use recent financing to further deploy TellDx globally and to advance TellRx programs in early-stage development. Strategic agreements announced concurrently — an exclusive TellDx license to Genetron for greater China and deployment at ARUP Laboratories in the U.S. — are intended to accelerate global commercialization and research adoption.